Advertisement Dabigatran etexilate found superior to warfarin in study - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Dabigatran etexilate found superior to warfarin in study

RE-LY trial has demonstrated that both doses of dabigatran etexilate (150mg bid and 110 mg bid) offer clinical benefits over warfarin when used in stroke prevention in patients with atrial fibrillation (AF).

The trial used a previously developed method to integrate ischemic and bleeding events as "ischemic stroke equivalents" to compare weighted benefit of two doses of dabigatran with each other and with warfarin.

The trial results have been presented at the American Heart Association Scientific Sessions, Los Angeles, US.

The data collected from 18,113 patients during the trial, has reiterated the benefits of dabigatran etexilate and has also provided physicians an approach to tailor treatment based upon individual patient characteristics and patient and physician preferences.